Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Krystal Biotech (KRYS) over the last 9 years, with Dec 2024 value amounting to $27.0 million.

  • Krystal Biotech's Cash from Financing Activities rose 10.22% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.5 million, marking a year-over-year decrease of 116.66%. This contributed to the annual value of $27.0 million for FY2024, which is 86.68% down from last year.
  • As of FY2024, Krystal Biotech's Cash from Financing Activities stood at $27.0 million, which was down 86.68% from $202.8 million recorded in FY2023.
  • Krystal Biotech's Cash from Financing Activities' 5-year high stood at $347.7 million during FY2021, with a 5-year trough of $27.0 million in FY2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $35.3 million (2022), whereas its average is $88.4 million.
  • Per our database at Business Quant, Krystal Biotech's Cash from Financing Activities tumbled by 89.83% in 2022 and then spiked by 473.60% in 2023.
  • Krystal Biotech's Cash from Financing Activities (Yearly) stood at $118.0 million in 2020, then surged by 194.60% to $347.7 million in 2021, then plummeted by 89.83% to $35.3 million in 2022, then soared by 473.60% to $202.8 million in 2023, then tumbled by 86.68% to $27.0 million in 2024.